The global chronic obstructive pulmonary disease (COPD) therapeutics market is set to experience significant growth, with a market value of USD 12,144.1 million in 2023. According to recent industry projections, the market is anticipated to reach USD 20,035.5 million by 2033, registering a compound annual growth rate (CAGR) of 5.1% over the forecast period.
The expansion of the COPD therapeutics market is largely attributed to the increasing prevalence of smoking and genetic disorders, which are key risk factors for the development of COPD. The rising number of individuals affected by these conditions drives demand for effective therapeutic solutions aimed at managing and alleviating the symptoms of COPD.
During the historical period from 2018 to 2022, the market registered a CAGR of 4.8%, reflecting steady growth in the adoption of COPD treatments. As awareness of COPD and its risk factors continues to increase, coupled with advancements in therapeutic options, the market is well-positioned for continued growth.
Request Your Detailed – Report Sample
Surgical Procedures for Serious Instances:
Surgery might be advised in COPD instances that are very severe. Treatment options include lung volume reduction surgery, lung transplants, and bullectomies. To stop the disease’s progression and enhance patient outcomes, appropriate therapeutic care is crucial, as evidenced by the high prevalence of COPD.
- Combination Therapies Are Becoming More PopularThe market for COPD treatments is seeing an increase in patients’ preference for combination treatments over single prescriptions, or monotherapy. LABA-ICS (long-acting beta antagonist and inhaled corticosteroid) and LAMA-ICS (long-acting muscarinic antagonist and inhaled corticosteroid) are two examples of combination therapy that have the following benefits:Enhanced Effectiveness: When it comes to controlling COPD symptoms and raising patients’ quality of life, combination treatments work better than monotherapy.
Better Patient Outcomes: Combination medications provide a more successful treatment strategy for patients who do not respond well to bronchodilators or corticosteroids alone, which may increase demand for COPD therapeutics.
Key players:
- Pfizer Inc.
- Adamis Laboratories Inc.
- GlaxoSmithKline plc.
- AstraZeneca
- Merk & Co.
- Novartis AG
- Mylan N.V.
- Teva Pharmaceutical Industries
Customization Available: Here
Key Segments Profiled in the COPD Therapeutics Industry Survey
By Component:
- COPD Therapeutics Drug Class
- Bronchodilators
- Steroids
- Phosphodiesterase-4 inhibitors
- Theophylline
- Antibiotics
- COPD Therapeutics Delivery Systems
- Oral
- Inhalation
By End User:
- Hospitals
- Private Clinics
- Outpatient Departments
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Discover Extensive Market Analysis: Purchase Now to Access
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube